Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

Neurobiology of Disease
Marta VuckovićMichael W Jakowec

Abstract

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse serves as a model of basal ganglia injury and Parkinson's disease. The present study investigated the effects of MPTP-induced lesioning on associative memory, conditioned fear, and affective behavior. Male C57BL/6 mice were administered saline or MPTP and separate groups were evaluated at either 7 or 30 days post-lesioning. In the social transmission of food preference test, mice showed a significant decrease in preference for familiar food 30 days post-MPTP compared to controls. Mice at both 7 and 30 days post-MPTP lesioning had increased fear extinction compared to controls. High Performance Liquid Chromatography analysis of tissues homogenates showed dopamine and serotonin were depleted in the striatum, frontal cortex, and amygdala. No changes in anxiety or depression were detected by the tail suspension, sucrose preference, light-dark preference, or hole-board tests. In conclusion, acute MPTP lesioning regimen in mice causes impairments in associative memory and conditioned fear, no mood changes, and depletion of dopamine and serotonin throughout the brain.

References

Apr 1, 1992·The American Journal of Psychiatry·J L Cummings
Jun 1, 1992·Physiology & Behavior·F J Helmstetter
Nov 1, 1991·Journal of Neuropathology and Experimental Neurology·W Paulus, K Jellinger
Jan 1, 1989·Movement Disorders : Official Journal of the Movement Disorder Society·Y AgidM Ruberg
Feb 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·B PillonY Agid
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·J N Crawley
Sep 1, 1987·Journal of Microscopy·H J Gundersen, E B Jensen
Apr 1, 1986·Journal of Neurology, Neurosurgery, and Psychiatry·A M GothamC D Marsden
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·D H Passe, J C Walker
Apr 16, 1982·Science·J W Wright, J W Harding
Sep 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·V Jackson-LewisS Przedborski
Jan 1, 1997·Current Biology : CB·J H KoganA J Silva
Oct 9, 1998·Journal of Neuroscience Methods·G RozasJ L Labandeira-García
Jul 23, 1999·Annals of the New York Academy of Sciences·F A GuarraciB S Kapp
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J J Mann
Jun 9, 2000·Annual Review of Neuroscience·J E LeDoux
Feb 13, 2001·Postgraduate Medical Journal·K Walsh, G Bennett
Mar 13, 2001·Molecular Psychiatry·M Davis, P J Whalen
Apr 11, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·G M PetzingerJ W Langston
Jul 13, 2001·The Journal of Neuropsychiatry and Clinical Neurosciences·J R SlaughterM P Martens
Aug 18, 2001·Developmental Neuroscience·M W JakowecG M Petzinger
Jan 31, 2002·Molecular Neurobiology·S J Wood, M Toth
Feb 28, 2003·Journal of Neuroscience Methods·Jennifer L Tillerson, Gary W Miller
Mar 26, 2003·Journal of Psychiatric Research·Xiaoqing LiuHoward K Gershenfeld
Apr 24, 2003·Behavioral Neuroscience·Lana LedgerwoodJacquelyn Cranney
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Jul 22, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Tatyana StrekalovaPeter Gass

❮ Previous
Next ❯

Citations

Mar 20, 2010·Neurotoxicity Research·Trevor Archer, Anders Fredriksson
Dec 19, 2013·Neurotoxicity Research·Hanane KadarRita Raisman-Vozari
Jan 13, 2012·Neurobiology of Disease·Kimberly McDowell, Marie-Françoise Chesselet
Jan 19, 2016·International Immunopharmacology·Lisa A RiesbergKristen M Drescher
Oct 4, 2011·Neuroscience Letters·Twum A AnsahAriel Y Deutch
Jun 20, 2012·The European Journal of Neuroscience·Hanna S Lindgren, Stephen B Dunnett
May 27, 2016·Sleep Science·Ana Carolina D NosedaMarcelo M S Lima
Jul 10, 2010·Neuroscience and Biobehavioral Reviews·Karen L Eskow JaunarajsChristopher Bishop
Apr 3, 2014·Physiology & Behavior·Shih-Chun HoYing-Jui Ho
Sep 10, 2011·Neuropharmacology·Rui D S PredigerMaria A B F Vital
Sep 16, 2014·Frontiers in Behavioral Neuroscience·Alessandra Bonito-OlivaGilberto Fisone
Mar 10, 2010·Behavioural Brain Research·Tonya N TaylorGary W Miller
Jun 9, 2017·Nature Reviews. Neuroscience·Anthony H V SchapiraPeter Jenner
Dec 28, 2018·Acta Biologica Hungarica·Fedia RebahHouneida Attia
Feb 21, 2014·Pharmacological Reports : PR·Krystyna Ossowska, Elżbieta Lorenc-Koci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.